IL-2Rα biased agonists have been shown to significantly expand tumor-specific CD8+ T cells (TSTs) and PD-1+CD25+CD8+ tumor-infiltrating lymphocytes (TILs) (61), although they may also promote Tregs proliferation. Here, CD8A is linked to neoplasm.